| Autor: |
Park, Jae-Woo, Yoon, Jeungwon, Cho, Chong-Kwan, Lee, Yeon-Weol, Yoo, Hwa-Seung |
| Předmět: |
|
| Zdroj: |
Chinese Journal of Integrative Medicine; Jan2014, Vol. 20 Issue 1, p49-55, 7p |
| Abstrakt: |
Objective: To evaluate the efficacy of HangAm-Plus (HAP) on stage IV metastatic gastric cancer by analyzing the treated patients' overall survival outcome. Methods: Following the study eligibility, overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only ( n=18) and combined treatment of concurrent conventional chemotherapy and HAP ( n=26). Patient characteristics by gender, age, surgical intervention, Eastern Cooperative Oncology Group (ECOG) score, treatment duration (< 4 weeks or ⩾4 weeks), and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed. Results: The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%, respectively ( P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%, respectively ( P=0.001). Conclusions: The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage IV metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink